查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
神经生物标誌物的全球市场规模、份额和行业趋势分析报告：按类型、应用和地区划分的展望和预测，2022-2028 年
市场调查报告书
商品编码
1155445

神经生物标誌物的全球市场规模、份额和行业趋势分析报告：按类型、应用和地区划分的展望和预测，2022-2028 年

Global Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report By Type, By Application, By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 163 Pages | 订单完成后即时交付

价格

到 2028 年，神经生物标誌物的全球市场规模预计将达到 129 亿美元，在预测期内以 14.2% 的复合年增长率增长。

世界卫生组织 (WHO) 与联合国和国际劳工组织合作，制定了国际化学品安全计划，指出生物标誌物“可以在人体或其产品线中进行评估，并与后果或疾病发展。” “任何可能产生影响或可预见的物质、结构或程序。”

更深入的定义不仅考虑了疾病的发生和病程，还考虑了疾病的治疗和干预措施，以及毒素和营养素等无意的环境暴露。在更好的技术发明之前，神经系统疾病的生物标誌物很少，这使得研究人员很难通过分子分析来监测大脑健康。这有望实现侵入性更小的测试、更快的药物开发、更早的诊断和更有效的治疗。

COVID-19 影响分析

被称为 COVID-19 的全球突发公共卫生事件几乎影响了所有企业，其长期影响预计将在预测期内影响行业增长。. Diaceutics PLC（英国）癌症诊断率和生物标誌物检测率研究显示，2020 年 2 月至 2020 年 3 月期间，新诊断的转移性非小细胞肺癌患者有所减少。 KRAS、BRAF 和 EGFR 的检测率，这些支持优化选择造福特定患者的精准医疗药物的关键指标，也可能受到短短一个月的急剧下降的影响。

市场增长因素

伴随诊断的重要性与日俱增

在医疗领域，伴随诊断试剂和生物标誌物的重要性越来越高，对每种疾病的诊断、治疗和监测也在加强。它还可用于识别更有可能对某些治疗或药物产生反应的患者。这些诊断通常与特定的医学治疗密切相关。

个性化医疗概念的扩展

在个性化医疗中，生物标誌物非常重要，因为它们可用于诊断、预后预测和特定治疗的选择。随着传统诊断和治疗方法的各种缺点被指出，个性化医疗已经变得普遍。从癌症到免疫疾病，许多医学专业正在朝着基于患者基因谱和表型特征的个性化医疗方向发展。

市场製约因素

启动成本高，生物标誌物开发週期长

由于生物标誌物检测疾病的能力各不相同，因此对其进行评估需要时间。因此，验证既昂贵又耗时。因此，生物标誌物开发和验证的过程和时间表在所有生物标誌物类别中都是相似的，但有一些例外。

输入 Outlook

根据类型，神经生物标誌物市场分为基因组学、蛋白质组学、代谢组学等。到 2021 年，基因组学部分将在神经生物标誌物市场中占据重要的收入份额。神经系统疾病患病率增加、缺血性中风估计发病率增加、对最小干预的需求增加、临床测试技术进步、公众对基于基因组生物标誌物的个性化医疗意识的提高等正在推动基因组生物标誌物市场的扩张。

应用展望

按应用划分，神经生物标誌物市场分为帕金森病、阿尔茨海默病和多发性硬化症。由于临床试验、研究、药物开发的增加以及阿尔茨海默病患病率的上升，阿尔茨海默病细分市场在 2021 年获得了神经生物标誌物市场最大的收入份额。阿尔茨海默病 (AD) 药物开发在很大程度上依赖于生物标誌物。

区域展望

按地区划分，分析了北美、欧洲、亚太地区和拉美地区的神经生物标誌物市场。到 2021 年，北美部分在神经生物标誌物市场中的收入份额最高。越来越多的美国研究表明，在过去 25 年中，美国和其他高收入西方国家患阿尔茨海默病和其他形式痴呆症的特定年龄风险有所下降。

内容

第一章市场范围与研究方法

  • 市场定义
  • 目的
  • 市场规模
  • 细分
    • 全球神经生物标誌物市场，按类型分类
    • 神经生物标誌物的全球市场，按应用分类
    • 全球神经生物标誌物市场，按地区划分
  • 调查方法

第 2 章市场概述

  • 简介
    • 概览
      • 市场构成和情景
  • 影响市场的主要因素
    • 市场驱动力
    • 市场製约因素

第 3 章神经生物标誌物的全球市场：按类型分类

  • 全球蛋白质组学市场：按地区
  • 全球基因组学市场：按地区
  • 全球代谢组学市场：按地区
  • 全球各地区的其他市场

第 4 章神经生物标誌物的全球市场：按应用

  • 全球阿尔茨海默病市场：按地区
  • 全球帕金森病市场：按地区
  • 多发性硬化症全球市场：按地区

第 5 章神经生物标誌物的全球市场：按地区

  • 北美
    • 按国家/地区划分的北美神经生物标誌物市场
      • 美国
      • 加拿大
      • 墨西哥
      • 其他北美地区
  • 欧洲
    • 欧洲神经生物标誌物市场：按国家/地区分类
      • 德国
      • 英国
      • 法国
      • 俄罗斯
      • 西班牙
      • 意大利
      • 其他欧洲
  • 亚太地区
    • 亚太地区神经生物标誌物的全国市场
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 新加坡
      • 其他亚太地区
  • 拉美
    • LAMEA 神经生物标誌物市场：按国家/地区分类
      • 巴西
      • 阿根廷
      • 阿联酋
      • 沙特阿拉伯
      • 南非
      • 尼日利亚
      • 拉美其他地区

第六章公司简介

  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad laboratories, Inc.
  • Merck Group
  • PerkinElmer, Inc.
  • Shimadzu Corporation
  • Thermo Fisher Scientific, Inc.
  • BioMerieux S.A
  • Myriad Genetics, Inc.
  • Quanterix Corporation
  • Neuro-Bio Ltd.

The Global Neurological Biomarkers Market size is expected to reach $12.9 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.

The term "biomarker," a portmanteau of "biological marker," refers to a large subclass of medical signs, or objective indicators of health status seen from the outside of the patient, which can be quantified precisely and consistently. Medical symptoms, on the other hand, are only those markers of health or disease that patients themselves may perceive. The literature contains several more detailed definitions of biomarkers, and they have a lot in common.

A biomarker is "a characteristic that is measured and evaluated objectively as an indicator of normal biochemical functions, pathogenic processes, or pharmacologic responses to a therapeutic intervention," according to the National Institutes of Health Biomarkers Definitions Working Group definition from 1998.

The World Health Organization (WHO), in collaboration with the United Nations and the International Labor Organization, established the International Program on Chemical Safety, which defines a biomarker as "any substance, structure, or procedure that can be evaluated in the body or its product lines and influence or predict the incidence of outcome or disease.

A definition that goes even further considers not only the occurrence and course of a disease, but also its treatment, interventions, and even inadvertent environmental exposure to substances like toxins or nutrients. Before the invention of better technology, it was difficult for researchers to monitor brain health by analyzing molecules since there were so few biomarkers for neurological illnesses. This entails less invasive testing, quicker medication development, earlier diagnosis, and hopefully more efficient therapies.

COVID-19 Impact Analysis

Almost every business has been impacted by the unmatched worldwide public health emergency known as COVID-19, and the long-term impacts are expected to influence industry growth throughout the course of the forecast period. According to research by Diaceutics PLC (UK) on the diagnosis and biomarker testing rates for various cancer types, the number of newly diagnosed patients with metastatic non-small cell lung cancer decreased between February 2020 and March 2020. The rates of KRAS, BRAF, and EGFR testing, which are important indicators supporting the optimal choice of precision medicine medicines that benefit particular patients, were also significantly influenced by this abrupt decline in just one month.

Market Growth Factor

Companion Diagnostics Are Becoming More Important

In the practice of medicine, companion diagnostics and biomarkers are becoming more and more important, which has enhanced disease-specific diagnosis, therapy, and monitoring. It can be used to identify patients who will likely respond well to specific treatments or drugs. These diagnostics frequently go hand in hand with certain medicine.

The Growing Concept of Individual Medicine

In customized medicine, biomarkers are crucial because they can be used for diagnosis, prognosis, and choosing specific treatments. Personalized medicine has grown in popularity over time as a result of the different drawbacks of conventional methods for diagnosis and treatment. Numerous medical specialties from cancer to immunological disorders are moving toward individualized patient care based on their genetic profiles and phenotypic traits.

Market Restraining Factor

High Startup Costs and Protracted Biomarker Development Cycles

Due to the variability in how well they perform in illness detection, evaluating biomarkers is a time-consuming process. As a result, the validation procedure grows expensive and time-consuming. The process and timetable for developing and validating biomarkers are therefore comparable across biomarker categories, with a few exceptions, because different categories of biomarkers frequently share common development and validation process phases.

Type Outlook

Based on the Type, the Neurological Biomarkers Market is segmented into Genomic, Proteomic, Metabolomic, and Others. The genomic segment acquired a significant revenue share in the neurological biomarkers market in 2021. Increased prevalence of neurological disorders, an increase in the estimated incidence of ischemic stroke, elevated demand for minimally procedures, technological advancements in clinical laboratory tests and rising public awareness of genomic biomarker-based personalized medicines are all contributing factors to the expansion of the genomic biomarkers market.

Application Outlook

On the basis of Application, the Neurological Biomarkers Market is divided into Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis. The Alzheimer's disease segment procured the largest revenue share in the neurological biomarkers market in 2021. due to an increase in clinical trials, research, and drug development as well as an increase in the prevalence of Alzheimer's disease. Drug development for Alzheimer's disease (AD) heavily relies on biomarkers.

Regional Outlook

Region-wise, the Neurological Biomarkers Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the highest revenue share in the neurological biomarkers market in 2021. The increase in American studies suggests a decrease in the age-specific risk of Alzheimer's disease and other forms of dementia in the United States and other high-income western nations over the previous 25 years.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMerieux S.A. and Myriad Genetics, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Proteomic
  • Genomic
  • Metabolomic
  • Others

By Application

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • F. HOFFMANN-LA ROCHE LTD.
  • Bio-Rad Laboratories, Inc.
  • Merck Group
  • PERKINELMER INC.
  • Shimadzu corporation
  • Thermo Fisher Scientific, Inc.
  • Quanterix Corporation
  • Neuro-Bio Ltd.
  • BioMerieux S.A.
  • Myriad Genetics, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Neurological Biomarkers Market, by Type
    • 1.4.2 Global Neurological Biomarkers Market, by Application
    • 1.4.3 Global Neurological Biomarkers Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenarios
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Neurological Biomarkers Market by Type

  • 3.1 Global Proteomic Market by Region
  • 3.2 Global Genomic Market by Region
  • 3.3 Global Metabolomic Market by Region
  • 3.4 Global Others Market by Region

Chapter 4. Global Neurological Biomarkers Market by Application

  • 4.1 Global Alzheimer's Disease Market by Region
  • 4.2 Global Parkinson's Disease Market by Region
  • 4.3 Global Multiple Sclerosis Market by Region

Chapter 5. Global Neurological Biomarkers Market by Region

  • 5.1 North America Neurological Biomarkers Market
    • 5.1.1 North America Neurological Biomarkers Market by Type
      • 5.1.1.1 North America Proteomic Market by Country
      • 5.1.1.2 North America Genomic Market by Country
      • 5.1.1.3 North America Metabolomic Market by Country
      • 5.1.1.4 North America Others Market by Country
    • 5.1.2 North America Neurological Biomarkers Market by Application
      • 5.1.2.1 North America Alzheimer's Disease Market by Country
      • 5.1.2.2 North America Parkinson's Disease Market by Country
      • 5.1.2.3 North America Multiple Sclerosis Market by Country
    • 5.1.3 North America Neurological Biomarkers Market by Country
      • 5.1.3.1 US Neurological Biomarkers Market
        • 5.1.3.1.1 US Neurological Biomarkers Market by Type
        • 5.1.3.1.2 US Neurological Biomarkers Market by Application
      • 5.1.3.2 Canada Neurological Biomarkers Market
        • 5.1.3.2.1 Canada Neurological Biomarkers Market by Type
        • 5.1.3.2.2 Canada Neurological Biomarkers Market by Application
      • 5.1.3.3 Mexico Neurological Biomarkers Market
        • 5.1.3.3.1 Mexico Neurological Biomarkers Market by Type
        • 5.1.3.3.2 Mexico Neurological Biomarkers Market by Application
      • 5.1.3.4 Rest of North America Neurological Biomarkers Market
        • 5.1.3.4.1 Rest of North America Neurological Biomarkers Market by Type
        • 5.1.3.4.2 Rest of North America Neurological Biomarkers Market by Application
  • 5.2 Europe Neurological Biomarkers Market
    • 5.2.1 Europe Neurological Biomarkers Market by Type
      • 5.2.1.1 Europe Proteomic Market by Country
      • 5.2.1.2 Europe Genomic Market by Country
      • 5.2.1.3 Europe Metabolomic Market by Country
      • 5.2.1.4 Europe Others Market by Country
    • 5.2.2 Europe Neurological Biomarkers Market by Application
      • 5.2.2.1 Europe Alzheimer's Disease Market by Country
      • 5.2.2.2 Europe Parkinson's Disease Market by Country
      • 5.2.2.3 Europe Multiple Sclerosis Market by Country
    • 5.2.3 Europe Neurological Biomarkers Market by Country
      • 5.2.3.1 Germany Neurological Biomarkers Market
        • 5.2.3.1.1 Germany Neurological Biomarkers Market by Type
        • 5.2.3.1.2 Germany Neurological Biomarkers Market by Application
      • 5.2.3.2 UK Neurological Biomarkers Market
        • 5.2.3.2.1 UK Neurological Biomarkers Market by Type
        • 5.2.3.2.2 UK Neurological Biomarkers Market by Application
      • 5.2.3.3 France Neurological Biomarkers Market
        • 5.2.3.3.1 France Neurological Biomarkers Market by Type
        • 5.2.3.3.2 France Neurological Biomarkers Market by Application
      • 5.2.3.4 Russia Neurological Biomarkers Market
        • 5.2.3.4.1 Russia Neurological Biomarkers Market by Type
        • 5.2.3.4.2 Russia Neurological Biomarkers Market by Application
      • 5.2.3.5 Spain Neurological Biomarkers Market
        • 5.2.3.5.1 Spain Neurological Biomarkers Market by Type
        • 5.2.3.5.2 Spain Neurological Biomarkers Market by Application
      • 5.2.3.6 Italy Neurological Biomarkers Market
        • 5.2.3.6.1 Italy Neurological Biomarkers Market by Type
        • 5.2.3.6.2 Italy Neurological Biomarkers Market by Application
      • 5.2.3.7 Rest of Europe Neurological Biomarkers Market
        • 5.2.3.7.1 Rest of Europe Neurological Biomarkers Market by Type
        • 5.2.3.7.2 Rest of Europe Neurological Biomarkers Market by Application
  • 5.3 Asia Pacific Neurological Biomarkers Market
    • 5.3.1 Asia Pacific Neurological Biomarkers Market by Type
      • 5.3.1.1 Asia Pacific Proteomic Market by Country
      • 5.3.1.2 Asia Pacific Genomic Market by Country
      • 5.3.1.3 Asia Pacific Metabolomic Market by Country
      • 5.3.1.4 Asia Pacific Others Market by Country
    • 5.3.2 Asia Pacific Neurological Biomarkers Market by Application
      • 5.3.2.1 Asia Pacific Alzheimer's Disease Market by Country
      • 5.3.2.2 Asia Pacific Parkinson's Disease Market by Country
      • 5.3.2.3 Asia Pacific Multiple Sclerosis Market by Country
    • 5.3.3 Asia Pacific Neurological Biomarkers Market by Country
      • 5.3.3.1 China Neurological Biomarkers Market
        • 5.3.3.1.1 China Neurological Biomarkers Market by Type
        • 5.3.3.1.2 China Neurological Biomarkers Market by Application
      • 5.3.3.2 Japan Neurological Biomarkers Market
        • 5.3.3.2.1 Japan Neurological Biomarkers Market by Type
        • 5.3.3.2.2 Japan Neurological Biomarkers Market by Application
      • 5.3.3.3 India Neurological Biomarkers Market
        • 5.3.3.3.1 India Neurological Biomarkers Market by Type
        • 5.3.3.3.2 India Neurological Biomarkers Market by Application
      • 5.3.3.4 Australia Neurological Biomarkers Market
        • 5.3.3.4.1 Australia Neurological Biomarkers Market by Type
        • 5.3.3.4.2 Australia Neurological Biomarkers Market by Application
      • 5.3.3.5 South Korea Neurological Biomarkers Market
        • 5.3.3.5.1 South Korea Neurological Biomarkers Market by Type
        • 5.3.3.5.2 South Korea Neurological Biomarkers Market by Application
      • 5.3.3.6 Singapore Neurological Biomarkers Market
        • 5.3.3.6.1 Singapore Neurological Biomarkers Market by Type
        • 5.3.3.6.2 Singapore Neurological Biomarkers Market by Application
      • 5.3.3.7 Rest of Asia Pacific Neurological Biomarkers Market
        • 5.3.3.7.1 Rest of Asia Pacific Neurological Biomarkers Market by Type
        • 5.3.3.7.2 Rest of Asia Pacific Neurological Biomarkers Market by Application
  • 5.4 LAMEA Neurological Biomarkers Market
    • 5.4.1 LAMEA Neurological Biomarkers Market by Type
      • 5.4.1.1 LAMEA Proteomic Market by Country
      • 5.4.1.2 LAMEA Genomic Market by Country
      • 5.4.1.3 LAMEA Metabolomic Market by Country
      • 5.4.1.4 LAMEA Others Market by Country
    • 5.4.2 LAMEA Neurological Biomarkers Market by Application
      • 5.4.2.1 LAMEA Alzheimer's Disease Market by Country
      • 5.4.2.2 LAMEA Parkinson's Disease Market by Country
      • 5.4.2.3 LAMEA Multiple Sclerosis Market by Country
    • 5.4.3 LAMEA Neurological Biomarkers Market by Country
      • 5.4.3.1 Brazil Neurological Biomarkers Market
        • 5.4.3.1.1 Brazil Neurological Biomarkers Market by Type
        • 5.4.3.1.2 Brazil Neurological Biomarkers Market by Application
      • 5.4.3.2 Argentina Neurological Biomarkers Market
        • 5.4.3.2.1 Argentina Neurological Biomarkers Market by Type
        • 5.4.3.2.2 Argentina Neurological Biomarkers Market by Application
      • 5.4.3.3 UAE Neurological Biomarkers Market
        • 5.4.3.3.1 UAE Neurological Biomarkers Market by Type
        • 5.4.3.3.2 UAE Neurological Biomarkers Market by Application
      • 5.4.3.4 Saudi Arabia Neurological Biomarkers Market
        • 5.4.3.4.1 Saudi Arabia Neurological Biomarkers Market by Type
        • 5.4.3.4.2 Saudi Arabia Neurological Biomarkers Market by Application
      • 5.4.3.5 South Africa Neurological Biomarkers Market
        • 5.4.3.5.1 South Africa Neurological Biomarkers Market by Type
        • 5.4.3.5.2 South Africa Neurological Biomarkers Market by Application
      • 5.4.3.6 Nigeria Neurological Biomarkers Market
        • 5.4.3.6.1 Nigeria Neurological Biomarkers Market by Type
        • 5.4.3.6.2 Nigeria Neurological Biomarkers Market by Application
      • 5.4.3.7 Rest of LAMEA Neurological Biomarkers Market
        • 5.4.3.7.1 Rest of LAMEA Neurological Biomarkers Market by Type
        • 5.4.3.7.2 Rest of LAMEA Neurological Biomarkers Market by Application

Chapter 6. Company Profiles

  • 6.1 F. Hoffmann-La Roche Ltd.
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 Bio-Rad laboratories, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expenses
  • 6.3 Merck Group
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expense
    • 6.3.5 Recent strategies and developments:
      • 6.3.5.1 Partnerships, Collaborations, and Agreements:
  • 6.4 PerkinElmer, Inc.
    • 6.4.1 Company Overview
    • 6.4.1 Financial Analysis
    • 6.4.2 Segmental and Regional Analysis
    • 6.4.3 Research & Development Expense
  • 6.5 Shimadzu Corporation
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental and Regional Analysis
  • 6.6 Thermo Fisher Scientific, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
  • 6.7 BioMerieux S.A.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Segmental and Regional Analysis
    • 6.7.4 Research & Development Expenses
  • 6.8 Myriad Genetics, Inc.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Segmental Analysis
    • 6.8.4 Research & Development Expenses
  • 6.9 Quanterix Corporation
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental and Regional Analysis
    • 6.9.4 Research & Development Expenses
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Partnerships, Collaborations, and Agreements:
  • 6.10. Neuro-Bio Ltd.
    • 6.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 Global Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 2 Global Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 3 Global Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Global Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Global Proteomic Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Proteomic Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Genomic Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Genomic Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Metabolomic Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global Metabolomic Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 12 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 13 Global Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 14 Global Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 15 Global Alzheimer's Disease Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Alzheimer's Disease Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Parkinson's Disease Market by Region, 2018 - 2021, USD Million
  • TABLE 18 Global Parkinson's Disease Market by Region, 2022 - 2028, USD Million
  • TABLE 19 Global Multiple Sclerosis Market by Region, 2018 - 2021, USD Million
  • TABLE 20 Global Multiple Sclerosis Market by Region, 2022 - 2028, USD Million
  • TABLE 21 Global Neurological Biomarkers Market by Region, 2018 - 2021, USD Million
  • TABLE 22 Global Neurological Biomarkers Market by Region, 2022 - 2028, USD Million
  • TABLE 23 North America Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 24 North America Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 25 North America Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 26 North America Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 27 North America Proteomic Market by Country, 2018 - 2021, USD Million
  • TABLE 28 North America Proteomic Market by Country, 2022 - 2028, USD Million
  • TABLE 29 North America Genomic Market by Country, 2018 - 2021, USD Million
  • TABLE 30 North America Genomic Market by Country, 2022 - 2028, USD Million
  • TABLE 31 North America Metabolomic Market by Country, 2018 - 2021, USD Million
  • TABLE 32 North America Metabolomic Market by Country, 2022 - 2028, USD Million
  • TABLE 33 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 34 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 35 North America Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 36 North America Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 37 North America Alzheimer's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 38 North America Alzheimer's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 39 North America Parkinson's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 40 North America Parkinson's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 41 North America Multiple Sclerosis Market by Country, 2018 - 2021, USD Million
  • TABLE 42 North America Multiple Sclerosis Market by Country, 2022 - 2028, USD Million
  • TABLE 43 North America Neurological Biomarkers Market by Country, 2018 - 2021, USD Million
  • TABLE 44 North America Neurological Biomarkers Market by Country, 2022 - 2028, USD Million
  • TABLE 45 US Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 46 US Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 47 US Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 48 US Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 49 US Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 50 US Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 51 Canada Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 52 Canada Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 53 Canada Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 54 Canada Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 55 Canada Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 56 Canada Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 57 Mexico Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 58 Mexico Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 59 Mexico Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 60 Mexico Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 61 Mexico Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 62 Mexico Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 63 Rest of North America Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 64 Rest of North America Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 65 Rest of North America Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 66 Rest of North America Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 67 Rest of North America Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 68 Rest of North America Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 69 Europe Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 70 Europe Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 71 Europe Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 72 Europe Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 73 Europe Proteomic Market by Country, 2018 - 2021, USD Million
  • TABLE 74 Europe Proteomic Market by Country, 2022 - 2028, USD Million
  • TABLE 75 Europe Genomic Market by Country, 2018 - 2021, USD Million
  • TABLE 76 Europe Genomic Market by Country, 2022 - 2028, USD Million
  • TABLE 77 Europe Metabolomic Market by Country, 2018 - 2021, USD Million
  • TABLE 78 Europe Metabolomic Market by Country, 2022 - 2028, USD Million
  • TABLE 79 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 80 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 81 Europe Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 82 Europe Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 83 Europe Alzheimer's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 84 Europe Alzheimer's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 85 Europe Parkinson's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 86 Europe Parkinson's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 87 Europe Multiple Sclerosis Market by Country, 2018 - 2021, USD Million
  • TABLE 88 Europe Multiple Sclerosis Market by Country, 2022 - 2028, USD Million
  • TABLE 89 Europe Neurological Biomarkers Market by Country, 2018 - 2021, USD Million
  • TABLE 90 Europe Neurological Biomarkers Market by Country, 2022 - 2028, USD Million
  • TABLE 91 Germany Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 92 Germany Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 93 Germany Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 94 Germany Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 95 Germany Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 96 Germany Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 97 UK Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 98 UK Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 99 UK Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 100 UK Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 101 UK Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 102 UK Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 103 France Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 104 France Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 105 France Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 106 France Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 107 France Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 108 France Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 109 Russia Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 110 Russia Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 111 Russia Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 112 Russia Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 113 Russia Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 114 Russia Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 115 Spain Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 116 Spain Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 117 Spain Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 118 Spain Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 119 Spain Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 120 Spain Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 121 Italy Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 122 Italy Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 123 Italy Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 124 Italy Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 125 Italy Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 126 Italy Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 127 Rest of Europe Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 128 Rest of Europe Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 129 Rest of Europe Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 130 Rest of Europe Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 131 Rest of Europe Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 132 Rest of Europe Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 133 Asia Pacific Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 134 Asia Pacific Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 135 Asia Pacific Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 136 Asia Pacific Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 137 Asia Pacific Proteomic Market by Country, 2018 - 2021, USD Million
  • TABLE 138 Asia Pacific Proteomic Market by Country, 2022 - 2028, USD Million
  • TABLE 139 Asia Pacific Genomic Market by Country, 2018 - 2021, USD Million
  • TABLE 140 Asia Pacific Genomic Market by Country, 2022 - 2028, USD Million
  • TABLE 141 Asia Pacific Metabolomic Market by Country, 2018 - 2021, USD Million
  • TABLE 142 Asia Pacific Metabolomic Market by Country, 2022 - 2028, USD Million
  • TABLE 143 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 144 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 145 Asia Pacific Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 146 Asia Pacific Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 147 Asia Pacific Alzheimer's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 148 Asia Pacific Alzheimer's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 149 Asia Pacific Parkinson's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 150 Asia Pacific Parkinson's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 151 Asia Pacific Multiple Sclerosis Market by Country, 2018 - 2021, USD Million
  • TABLE 152 Asia Pacific Multiple Sclerosis Market by Country, 2022 - 2028, USD Million
  • TABLE 153 Asia Pacific Neurological Biomarkers Market by Country, 2018 - 2021, USD Million
  • TABLE 154 Asia Pacific Neurological Biomarkers Market by Country, 2022 - 2028, USD Million
  • TABLE 155 China Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 156 China Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 157 China Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 158 China Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 159 China Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 160 China Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 161 Japan Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 162 Japan Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 163 Japan Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 164 Japan Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 165 Japan Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 166 Japan Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 167 India Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 168 India Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 169 India Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 170 India Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 171 India Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 172 India Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 173 Australia Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 174 Australia Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 175 Australia Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 176 Australia Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 177 Australia Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 178 Australia Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 179 South Korea Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 180 South Korea Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 181 South Korea Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 182 South Korea Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 183 South Korea Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 184 South Korea Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 185 Singapore Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 186 Singapore Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 187 Singapore Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 188 Singapore Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 189 Singapore Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 190 Singapore Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 191 Rest of Asia Pacific Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 192 Rest of Asia Pacific Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 193 Rest of Asia Pacific Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 194 Rest of Asia Pacific Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 195 Rest of Asia Pacific Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 196 Rest of Asia Pacific Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 197 LAMEA Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 198 LAMEA Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 199 LAMEA Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 200 LAMEA Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 201 LAMEA Proteomic Market by Country, 2018 - 2021, USD Million
  • TABLE 202 LAMEA Proteomic Market by Country, 2022 - 2028, USD Million
  • TABLE 203 LAMEA Genomic Market by Country, 2018 - 2021, USD Million
  • TABLE 204 LAMEA Genomic Market by Country, 2022 - 2028, USD Million
  • TABLE 205 LAMEA Metabolomic Market by Country, 2018 - 2021, USD Million
  • TABLE 206 LAMEA Metabolomic Market by Country, 2022 - 2028, USD Million
  • TABLE 207 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 208 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 209 LAMEA Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 210 LAMEA Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 211 LAMEA Alzheimer's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 212 LAMEA Alzheimer's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 213 LAMEA Parkinson's Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 214 LAMEA Parkinson's Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 215 LAMEA Multiple Sclerosis Market by Country, 2018 - 2021, USD Million
  • TABLE 216 LAMEA Multiple Sclerosis Market by Country, 2022 - 2028, USD Million
  • TABLE 217 LAMEA Neurological Biomarkers Market by Country, 2018 - 2021, USD Million
  • TABLE 218 LAMEA Neurological Biomarkers Market by Country, 2022 - 2028, USD Million
  • TABLE 219 Brazil Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 220 Brazil Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 221 Brazil Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 222 Brazil Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 223 Brazil Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 224 Brazil Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 225 Argentina Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 226 Argentina Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 227 Argentina Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 228 Argentina Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 229 Argentina Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 230 Argentina Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 231 UAE Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 232 UAE Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 233 UAE Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 234 UAE Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 235 UAE Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 236 UAE Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 237 Saudi Arabia Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 238 Saudi Arabia Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 239 Saudi Arabia Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 240 Saudi Arabia Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 241 Saudi Arabia Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 242 Saudi Arabia Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 243 South Africa Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 244 South Africa Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 245 South Africa Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 246 South Africa Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 247 South Africa Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 248 South Africa Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 249 Nigeria Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 250 Nigeria Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 251 Nigeria Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 252 Nigeria Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 253 Nigeria Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 254 Nigeria Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 255 Rest of LAMEA Neurological Biomarkers Market, 2018 - 2021, USD Million
  • TABLE 256 Rest of LAMEA Neurological Biomarkers Market, 2022 - 2028, USD Million
  • TABLE 257 Rest of LAMEA Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
  • TABLE 258 Rest of LAMEA Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
  • TABLE 259 Rest of LAMEA Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
  • TABLE 260 Rest of LAMEA Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
  • TABLE 261 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
  • TABLE 262 Key Information - Bio-Rad Laboratories, Inc.
  • TABLE 263 key Information - Merck GrouP
  • TABLE 264 key Information - PerkinElmer, Inc.
  • TABLE 265 Key Information - Shimadzu Corporation
  • TABLE 266 Key Information - Thermo Fisher Scientific, Inc.
  • TABLE 267 Key information - BioMerieux S.A.
  • TABLE 268 Key Information - Myriad Genetics, Inc.
  • TABLE 269 Key Information - QUANTERIX CORPORATION
  • TABLE 270 Key Information - Neuro-Bio Ltd.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Neurological Biomarkers Market Share by Type, 2021
  • FIG 3 Global Neurological Biomarkers Market Share by Type, 2028
  • FIG 4 Global Neurological Biomarkers Market by Type, 2018 - 2028, USD Million
  • FIG 5 Global Neurological Biomarkers Market by Application, 2021
  • FIG 6 Global Neurological Biomarkers Market by Application, 2028
  • FIG 7 Global Neurological Biomarkers Market by Application, 2018 - 2028, USD Million
  • FIG 8 Global Neurological Biomarkers Market Share by Region, 2021
  • FIG 9 Global Neurological Biomarkers Market Share by Region, 2028
  • FIG 10 Global Neurological Biomarkers Market by Region, 2018 - 2028, USD Million